Loading...
Market
Which pharmaceutical company will lead Anti-IL-11 drug development by end of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Moderna • 25%
Roche • 25%
Other • 25%
Company announcements and industry reports
Story
Study Shows Anti-IL-11 Drug Extends Lifespan of Mice by 25%, Reduces Cancer and Gray Hair
Jul 17, 2024, 04:25 PM
A recent study published in Nature has shown that inhibiting interleukin-11 (IL-11), a pro-inflammatory cytokine, can significantly extend the lifespan of mice. The research demonstrated that both genetic deletion and pharmacological inhibition of IL-11 increased the lifespan of laboratory mice by nearly 25%. The treated mice, referred to as 'supermodel grannies' due to their youthful appearance, were healthier, stronger, and exhibited fewer age-related health problems. The study found that male mice experienced a 22.5% increase in median lifespan. Additionally, the treatment reduced the incidence of cancer and gray hair. Anti-IL-11 therapies are already in human clinical trials, raising hopes for their potential application in extending human lifespan and improving healthspan.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Not approved by any major regulatory body • 25%
Nature • 25%
The Lancet • 25%
JAMA • 25%
Other • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Roche • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%